+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab

Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab

American Journal of Gastroenterology 97(2): 499-500

(PDF same-day service: $19.90)

Accession: 035980822

Download citation: RISBibTeXText

PMID: 11866306

DOI: 10.1111/j.1572-0241.2002.05514.x

Related references

Infliximab in the treatment of Crohn's disease -- a practical approach. Infliximab and chronic Crohn's disease--Consensus statement of the Working Group on Chronic Inflammatory Crohn's Diseases of the OGGH. Zeitschrift für Gastroenterologie 42(10): 1256-1263, 2004

Treatment of recurrent Crohn's uveitis with infliximab. American Journal of Gastroenterology 103(8): 2150-2151, 2008

Fulminant acute hepatitis B after infliximab treatment in Crohn's disease. La Tunisie Medicale 92(5): 349-350, 2015

Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment. American Journal of Gastroenterology 95(11): 3334-3336, 2000

An epidemiology of research to avoid dissipation of resources of the Italian national health service. Epidemiologia E Prevenzione 42(1): 96-97, 2018

A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn's disease. Korean Journal of Gastroenterology 63(5): 308-312, 2016

The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn's Disease: Experience from a Tertiary Medical Center in China. Biomed Research International 2016(): 8648307-8648307, 2016

Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease. Physiological Research 52(1): 89-93, 2003

Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease. Journal of Crohn's & Colitis 9(3): 238-245, 2015

Successful Treatment with Infliximab for Refractory Uveitis in a Hemodialysis Patient with Behçet's Disease and a Review of the Literature for Infliximab Use in Patients on Hemodialysis. Internal Medicine 54(12): 1553-1557, 2015

Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease. Danish Medical Journal 60(4): B4616-B4616, 2014

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab. Plos One 10(12): E0144900-E0144900, 2016

Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Internal Medicine Journal 31(3): 146-150, 2001

Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial. Inflammatory Bowel Diseases 21(9): 2114-2122, 2016

Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. A BALANCING VIEW: lifetime channeling of infliximab for crohn's disease. American Journal of Gastroenterology 100(7): 1438-1439, 2005